-
Nov 8, 2024 | 
ajmc.com | Toby Maher
OpinionVideoNovember 8, 2024Author(s): Timely intervention in oncology is critical for improving survival rates, disease progression, and quality of life. Delays in treatment can result in advanced disease stages, reduced treatment efficacy, and increased morbidity. Contributing factors to treatment delays include healthcare system inefficiencies, patient-related barriers, and logistical challenges.
-
Oct 31, 2024 | 
ajmc.com | Toby Maher
OpinionVideoOctober 31, 2024Author(s): Comorbidities can obscure IPF symptoms, leading to diagnostic delays or misdiagnoses, complicating the clinical presentation. Comprehensive evaluation is crucial to tailor treatment plans addressing both IPF and comorbidities effectively. Comorbidities may limit therapeutic options, necessitate medication adjustments, or require additional interventions.
-
Oct 24, 2024 | 
ajmc.com | Toby Maher
OpinionVideoOctober 24, 2024Author(s): IPF diagnosis relies on clinical evaluation, HRCT, and occasionally lung biopsy to identify usual interstitial pneumonia patterns. The average time to IPF diagnosis can be delayed up to two years due to symptom overlap with other conditions. Early diagnosis is crucial for influencing disease progression and treatment efficacy, enabling timely intervention with antifibrotic therapies.
-
Oct 17, 2024 | 
ajmc.com | Toby Maher
OpinionVideoOctober 17, 2024Author(s):Toby Maher, MD, PhD, discusses how idiopathic pulmonary fibrosis (IPF) is a specific form of interstitial lung disease characterized by progressive lung scarring, which leads to significant respiratory impairment and distinct clinical challenges compared with other interstitial lung diseases. Video content above is prompted by the following:What is IPF, and how does IPF compare with interstitial lung disease?
-
Oct 17, 2024 | 
ajmc.com | Toby Maher
OpinionVideoOctober 17, 2024Author(s): IPF is a chronic, progressive lung disease marked by lung tissue thickening and scarring, leading to reduced lung function. It is a specific type of interstitial lung disease, which includes various disorders affecting lung interstitium. Unlike other ILDs, IPF is idiopathic, with no known cause, and generally has a poorer prognosis.
-
Aug 13, 2024 | 
digitalcommons.library.tmc.edu | Toby Maher |Shervin Assassi |Arata Azuma |Vincent Cottin
INTRODUCTION: Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF and IPF, suggesting a similar underlying pathology relating to pulmonary fibrosis. Following positive results in a phase II study in IPF, this phase III study will investigate the efficacy and safety of BI 1015550 in patients with PPF (FIBRONEER-ILD).
-
Jun 27, 2024 | 
bmjopenrespres.bmj.com | Toby Maher |Michael Kreuter |David Lederer |Kevin Brown
Interstitial lung disease Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2) Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.
-
Jun 27, 2024 | 
bmjopenrespres.bmj.com | Toby Maher |Shervin Assassi |Arata Azuma |Vincent Cottin
Interstitial lung disease Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD) Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.
-
Apr 22, 2024 | 
jamanetwork.com | Toby Maher
Abstract
Importance
Interstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation and/or fibrosis of the lung parenchyma associated with progressive dyspnea that frequently results in end-stage respiratory failure. In the US, ILD affects approximately 650 000 people and causes approximately 25 000 to 30 000 deaths per year.
-
Feb 19, 2024 | 
futuremedicine.com | Toby Maher |Arata Azuma |Vincent Cottin |Shervin Assassi
This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original articles hereLink to original articles hereAcknowledgmentsThe authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of the manuscript.
